Table 1.
Cancer-directed drugs—potential Medicare savings with MCCPDC 30C and 90C purchasing.
| Medication ranking by Medicare claim volume | Generic drug name | Estimated Medicare savings at MCCPDC 30C pricing (2023 USD) | Percent savings w MCCPDC 30C | Estimated Medicare savings at MCCPDC 90C pricing (2023 USD) | Percent savings w MCCPDC 90C |
|---|---|---|---|---|---|
| 1 | Anastrozole | −$2 743 813.96 | −7% | $14 927 185.99 | 40% |
| 2 | Letrozole | $4 495 247.72 | 21% | $13 111 760.93 | 60% |
| 10 | Tamoxifen citrate | $1 902 497.07 | 14% | $6 556 799.92 | 47% |
| 19 | Abiraterone acetate | $520 217 617.57 | 95% | $524 155 167.97 | 96% |
| 30 | Imatinib mesylate | $240 870 258.65 | 97% | $241 868 199.54 | 97% |
| 155 | Erlotinib HCl | $19 689 307.21 | 97% | $19 744 484.63 | 97% |
| 164 | Methotrexate sodium | $19 405 220.49 | 34% | $37 473 605.19 | 66% |